59 related articles for article (PubMed ID: 27377533)
1. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
[TBL] [Abstract][Full Text] [Related]
2. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
Lamers CH; Langeveld SC; Groot-van Ruijven CM; Debets R; Sleijfer S; Gratama JW
Cancer Immunol Immunother; 2007 Dec; 56(12):1875-83. PubMed ID: 17479266
[TBL] [Abstract][Full Text] [Related]
3. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
[TBL] [Abstract][Full Text] [Related]
4. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
5. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract][Full Text] [Related]
6. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
[TBL] [Abstract][Full Text] [Related]
7. Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Maude SL; Barrett D; Teachey DT; Grupp SA
Cancer J; 2014; 20(2):119-22. PubMed ID: 24667956
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Thistlethwaite FC; Elkord E; Griffiths RW; Burt DJ; Shablak AM; Campbell JD; Gilham DE; Austin EB; Stern PL; Hawkins RE
Cancer Immunol Immunother; 2008 May; 57(5):623-34. PubMed ID: 17899077
[TBL] [Abstract][Full Text] [Related]
9. Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-gamma production of lymphocytes.
Ikemoto S; Wada S; Kamizuru M; Hayahara N; Kishimoto T; Maekawa M
Cancer Immunol Immunother; 1992; 34(5):289-93. PubMed ID: 1540974
[TBL] [Abstract][Full Text] [Related]
10. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
11. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
[TBL] [Abstract][Full Text] [Related]
12. Most Do, but Some Do Not: CD4⁺CD25
Hombach AA; Abken H
Cancers (Basel); 2017 Aug; 9(9):. PubMed ID: 28850063
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
Dhupkar P; Gordon N
Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.
Chen KH; Wada M; Firor AE; Pinz KG; Jares A; Liu H; Salman H; Golightly M; Lan F; Jiang X; Ma Y
Oncotarget; 2016 Aug; 7(35):56219-56232. PubMed ID: 27494836
[TBL] [Abstract][Full Text] [Related]
15. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
[TBL] [Abstract][Full Text] [Related]
16. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract][Full Text] [Related]
17. T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.
Klaver Y; van Steenbergen SC; Sleijfer S; Debets R; Lamers CH
Front Immunol; 2016; 7():648. PubMed ID: 28082983
[TBL] [Abstract][Full Text] [Related]
18. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
[TBL] [Abstract][Full Text] [Related]
19. [Progress of interleukin-6-related antibodies in the treatment of multiple myeloma].
Ren L; Liu P
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):525-528. PubMed ID: 34384164
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
